The GlaxoSmithKline (GSK) Bangladesh’s earnings per share (EPS) soared 206 per cent in April-June (Q2) quarter of 2019 compared to the same period last year.
The multinational company’s earnings per share stood at Tk 11.19 for April-June 2019 as against Tk 3.65 for April-June 2018, according to an official disclosure on Thursday.
In six months for January-June 2019, its EPS was Tk 22.25 for as against Tk 15.14 for January-June 2018.
The company’s net operating cash flow per share (NOCFPS) was Tk 37.66 for January-June 2019 as against Tk 29.94 for January-June 2018.
The net asset value (NAV) per share was Tk 72.57 as on June 30, 2019 and Tk. 178.49 as on June 30, 2018.
The company also informed that net asset value (NAV) per share is calculated by dividing shareholders’ equity with total number of shares.
The shareholders’ equity of April-June 2019 has decreased by 59.34 per cent in comparison with that of same period in the previous year (Tk 874,154,665.45 in Q2 2019 vs Tk 2,150,184,321.98 in Q2 2018).
In the year 2018, significant loss was recognised, resulting in significant reduction in shareholders’ equity as on December 2019, it said.
In Q2 2019, Tk 53 per share final dividend was paid to shareholders. A valuation of retirement fund was carried out in Q2 2019 and an actuarial loss was recognized in other comprehensive income.
Consequently, shareholders’ equity as on June 30, 2019 has reduced in comparison to that of June 30, 2018, said the company.
Last year, GSK Bangladesh shut pharmaceuticals unit in the country due to incurring loss. However, the company continues with its profitable consumer health care business that produces items like Horlicks, Sensodyne and Glaxose-D.
The company’s share closed at Tk 1,452.20 on Wednesday at the Dhaka Stock Exchange.
The company, which was listed on the DSE in 1976, disbursed 530 per cent cash dividend in 2018.
The company’s paid-up capital is Tk 120.46 million, authorised capital is Tk 200 million and the total number of securities is 12.04 million.
The sponsor-directors own 81.98 per cent stake in the company, while institutional investors own 16.13 per cent, foreign investors 0.36 per cent and the general public only 1.53 per cent as of June 30, 2019.
